New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
08:15 EDTTEVAFDA approves expanded label for Teva's Azilect
Teva Pharmaceutical Industries announced the U.S. Food and Drug Administration has expanded the indication for AZILECT from monotherapy and adjunct to levodopa to now include adjunct to dopamine agonists. The new indication reflects that AZILECT can be used alone or in combination with other Parkinson's disease medications. The approval reinforces the growing clinical evidence demonstrating the benefit of AZILECT across all stages of PD. The FDA approval of the expanded label is based on a supplemental new drug application submitted by Teva, supported by data from the ANDANTE study. The study demonstrated AZILECT provides a clinical benefit by significantly improving total Unified Parkinson's Disease Rating Scale scores compared to placebo in patients on DA monotherapy, while demonstrating tolerability.
News For TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
10:28 EDTTEVASenate Health, Education, Labor & Pensions Committee to hold a hearing
The Subcommittee on Primary Health and Aging holds a hearing entitled, "Why Are Some Generic Drugs Skyrocketing In Price?" with President & CEO Vigodman of Teva Pharmaceutical and President & CEO Bedrosian of Lannett Company on November 20 at 1 pm. Webcast Link
07:42 EDTTEVAIntellipharmaceutics notes launch of 5mg strength Focalin XR by Teva
Subscribe for More Information
November 18, 2014
11:22 EDTTEVATeva patent victory over Warner Chilcott, Roche affirmed
The U.S. Court of Appeals for the Federal Circuit ruled that a district court was correct to grant summary judgment to Teva (TEVA) in a patent dispute with Warner Chilcott and Roche (RHHBY) over patents related to osteoporosis drug risedronate.
10:08 EDTTEVATeva calls active on renewed takeover chatter
Teva November 57 and 58 calls are active on total call volume of 21K contracts (2K puts) following renewed takeover chatter. November call option implied volatility is at 18, December is at 19; compared to its 26-week average of 24 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
09:47 EDTTEVARumor: Teva moves up on renewed takeover chatter
Subscribe for More Information
08:00 EDTTEVATeva launches liquid formulation of TREANDA injection in the U.S.
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use